During the past decade, Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 14 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 7 clinical trials were completed. i.e. 175% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie" #1 sponsor was "Hoffmann-La Roche" with 21 trials, followed by "Central European Cooperative Oncology Group" with 3 trials sponsored, "Arbeitsgemeinschaft medikamentoese Tumortherapie" with 2 trials sponsored, "Austrian Forum Against Cancer" with 1 trials sponsored and "Baxalta now part of Shire" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie" #1 collaborator was "Breast International Group" with 2 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "Amgen" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator and "Baxalta Innovations GmbH, now part of Shire" with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie" are "Breast Cancer" (11 trials), "Multiple Myeloma" (2 trials), "Adenocarcinoma of the Gastroesophageal Junction" (1 trials), "Atrial Fibrillation" (1 trials) and "Bladder Cancer" (1 trials). Many other conditions were trialed in "Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie" in a lesser frequency.

Most popular intervention types in "Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie" are "Drug" (30 trials), "Biological" (3 trials), "Procedure" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Docetaxel" (6 trials), "Paclitaxel" (5 trials), "Pertuzumab" (5 trials), "Atezolizumab" (4 trials) and "Placebo" (4 trials). Other intervention names were less common.

The vast majority of trials in "Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie" are 27 trials for "All" genders and 6 trials for "Female" genders.

Currently, there are NaN active trials in "Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie". undefined are not yet recruiting, 2 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 22 completed trials in Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 22 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".